Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
31 10 2023
Historique:
received: 12 04 2023
accepted: 27 10 2023
medline: 2 11 2023
pubmed: 1 11 2023
entrez: 1 11 2023
Statut: epublish

Résumé

The economic burden of influenza is a significant issue within healthcare system, related to higher medical costs particularly among the elderly. Yet, influenza vaccination rates in the elderly in Malaysia were considerably low as it is not part of Malaysia's national immunization program, with substantial mortality and morbidity consequences. Therefore, we conducted a cost-effectiveness analysis of quadrivalent influenza vaccine (QIV) for the elderly in Malaysia compared with the current no-vaccination policy. A static cost-utility model, with a lifetime horizon based on age, was used for the analysis to assess the cost-effectiveness and health outcomes associated with QIV. Univariate and probabilistic sensitivity analyses were performed to test the effects of variations in the parameters. The use of QIV in Malaysia's elderly population would prevent 66,326 potential influenza cases and 888 potential deaths among the elderly, leading to 10,048 potential quality-adjusted life years (QALYs) gained. The QIV would also save over USD 4.4 million currently spent on influenza-related hospitalizations and reduce productivity losses by approximately USD 21.6 million. The ICER per QALY gained from a third-party payer's perspective would be USD 2216, which is lower than the country's gross domestic product per capita. A QIV-based vaccination program in the elderly was found to be highly cost-effective, therefore would reduce the financial burden of managing influenza and reduce pre-mature death related to this disease.

Identifiants

pubmed: 37907537
doi: 10.1038/s41598-023-46079-y
pii: 10.1038/s41598-023-46079-y
pmc: PMC10618214
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18771

Informations de copyright

© 2023. The Author(s).

Références

Hum Vaccin Immunother. 2017 Jan 2;13(1):81-89
pubmed: 27624648
PLoS One. 2015 Jul 29;10(7):e0133606
pubmed: 26222538
Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
BMC Geriatr. 2020 Feb 18;20(1):70
pubmed: 32070291
Pharmacoeconomics. 2021 Jan;39(1):81-97
pubmed: 33230613
Clin Infect Dis. 2017 Oct 15;65(8):1289-1297
pubmed: 28525597
J Prev Med Hyg. 2017 Dec 30;58(4):E279-E287
pubmed: 29707658
Vaccine. 2021 Aug 23;39(36):5138-5145
pubmed: 34344553
Vaccine. 2015 Jan 29;33(5):734-41
pubmed: 25444791
Med J Malaysia. 2015 Jun;70(3):127-30
pubmed: 26248773
Hum Vaccin Immunother. 2016 Sep;12(9):2269-77
pubmed: 27184622
Vaccine. 2006 May 15;24(20):4417-26
pubmed: 16621187
Int J Environ Res Public Health. 2022 Mar 13;19(6):
pubmed: 35329059
PLoS One. 2019 Jan 25;14(1):e0209643
pubmed: 30682030
Vaccine. 2018 Feb 8;36(7):997-1007
pubmed: 29373192
Vaccine. 2007 Jun 28;25(27):5086-96
pubmed: 17544181
Bull World Health Organ. 2015 Feb 1;93(2):118-24
pubmed: 25883405
Vaccine. 2018 Jun 22;36(27):3960-3966
pubmed: 29801998
PLoS One. 2014 Jun 06;9(6):e98437
pubmed: 24905235
Braz J Infect Dis. 2018 Jan - Feb;22(1):1-10
pubmed: 29352897
Vaccine. 2020 Jul 6;38(32):5002-5008
pubmed: 32532543
Influenza Other Respir Viruses. 2020 May;14(3):286-293
pubmed: 32022411
BMC Infect Dis. 2022 Dec 15;22(1):943
pubmed: 36522615
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Southeast Asian J Trop Med Public Health. 2010 Nov;41(6):1368-73
pubmed: 21329312
Vaccine. 2020 Apr 29;38(20):3682-3689
pubmed: 32249017
Int J Environ Res Public Health. 2020 Feb 14;17(4):
pubmed: 32075182
Vaccine. 2018 Nov 19;36(48):7331-7337
pubmed: 30327213
Hum Vaccin Immunother. 2023 Dec 31;19(1):2170660
pubmed: 36728847
Qual Life Res. 2019 Jan;28(1):153-162
pubmed: 30317426
J Med Virol. 2019 Mar;91(3):498-502
pubmed: 30199092
Vaccine. 2018 Sep 18;36(39):5916-5925
pubmed: 30077480
BMC Health Serv Res. 2022 Jan 5;22(1):34
pubmed: 34986870
Hum Vaccin Immunother. 2014;10(5):1171-80
pubmed: 24609063
Hum Vaccin Immunother. 2018;14(8):1867-1873
pubmed: 29708843

Auteurs

Syed Mohamed Aljunid (SM)

Department of Public Health and Community Medicine, School of Medicine, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia. saljunid@gmail.com.
International Centre for Casemix and Clinical Coding, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia. saljunid@gmail.com.

Nur Syazana Mad Tahir (NS)

Department of Public Health Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia. nursyazana.mt@gmail.com.
Federal Government Administrative Centre, Ministry of Health Malaysia, Putrajaya, Malaysia. nursyazana.mt@gmail.com.

Aniza Ismail (A)

Department of Public Health Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.

Aznida Firzah Abdul Aziz (AF)

Department of Family Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

Amirah Azzeri (A)

Public Health Unit, Department of Primary Health Care, Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Nilai, Malaysia.

S A Zafirah (SA)

Faculty of Medicine and Defence Health, National Defence University of Malaysia, Kuala Lumpur, Malaysia.

Azimatun Noor Aizuddin (AN)

International Centre for Casemix and Clinical Coding, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.
Department of Public Health Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH